Oncology testing services company NeoGenomics Inc (NASDAQ: NEO) announced on Wednesday that it will present three key studies at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona from 13-17 September. The studies emphasise the value of circulating tumour DNA (ctDNA) analysis and next-generation sequencing (NGS) in advancing early cancer detection and personalised treatment.
Among the highlights, data from a real-world analysis show NGS testing for multiple gene fusions can identify four times more patients eligible for matched therapies than traditional methods. Another study on ctDNA in early-stage non-small cell lung cancer (NSCLC) pinpoints patients at high relapse risk, guiding more aggressive treatment strategies. A third trial explores ctDNA as a marker to inform treatment in high-risk melanoma, comparing combined anti-LAG-3 and anti-PD-1 therapies with anti-PD-1 alone.
NeoGenomics, headquartered in Fort Myers, FL, is a leader in cancer genetics testing, offering comprehensive services for healthcare providers and pharmaceutical clients across multiple certified laboratories in the US and UK.
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
hVIVO reports positive results from RSV antiviral human challenge trial
BerGenBio reveals preliminary safety data from Phase 1b BGBC016 study in first-line NSCLC patients
Liquidia and Pharmosa expand collaboration for inhaled treprostinil
Alvotech launches confirmatory study for Entyvio biosimilar
Merck's KEYTRUDA receives new approvals in Japan for lung and urothelial cancers
Innate Pharma receives FDA clearance of IND for IPH4502, a Nectin-4 targeting ADC for solid tumours
Intas Pharmaceuticals reports positive opinion for HETRONIFLY in Europe
Insilico Medicine reveals positive preliminary results from ISM001-055Phase IIa clinical trial
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
AbbVie advances solid tumour pipeline with new data at ESMO 2024
Amgen showcases promising data for IMDELLTRA in small cell lung cancer at WCLC 2024